0      0


AM21-37: The Dilemma of Anti - Donor Human Leukocyte Antigen Antibodies and ABO Mismatch in Allogeneic Hematopoietic Cell Transplantation


‐ Oct 19, 2021 10:00am

Expiration Date: Dec 31, 2023


Credits: None available.

Allogeneic hematopoietic cell transplantation (HCT) provides a curative therapeutic option for a number of hematologic diseases.

HLA mismatch has been associated with increased risks of acute graft versus host disease and inferior overall survival (OS), which nowadays can be overcome by utilizing post transplantation cyclophosphamide. Yet, a significant hinderance can occur, when the patient has developed antibodies (Ab’s) against donor HLA mismatched antigens, that can cause graft rejection and engraftment failure. This session will focus on the pathobiology of donor directed HLA Ab’s, on their clinical implications for the risk of rejection, and on current and novel Ab depletion strategies.

Major ABO donor / recipient mismatch associates with impaired engraftment, prolonged hemolysis and inferior OS. This session will focus on the pathobiology of ABO mismatches, will emphasize their clinical implications for clinical outcomes, including novel strategies beyond steroids and rituximab.

To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:

  • Judge the clinical relevance of donor human leukocyte antigen (HLA) directed antibodies on engraftment and outcome after allogeneic hematopoietic cell transplantation (HCT)
  • Apply HLA antibody depletion strategies in the clinical setting of HLA mismatch and the presence of HLA antibodies, and will be able to discuss current and novel antibody depletion strategies.
  • Judge the clinical impact of ABO mismatch on clinical outcomes after allogeneic HCT and will be able to utilize current and novel mitigation strategies

Moderator(s):

Speaker(s):

Disclosures

  • Richard Maziarz, MD:

    Consulting/patent royalties, licensing fees: Allovir, Artiva Therapeutics, Incyte, Novartis, Athersys; Research funding: Novartis, Allovir, Bristol Meyer-Squibb, Omeros; Other: DSMB participant for Athersys, Novartis, Vor Pharma

  • Gerhard Hildebrandt, MD:
    Stock Shareholder (self-managed): Axim Biotechnologies, GW Pharmaceuticals, Cardinal Health, Clovis Oncology, Cellectis, CVS Health, Bluebird Bio, Pfizer, AImmune Therapeutics, Medical PPTYS TR Inc., Caretrust Reit Inc.; Consultant: Morphosys, Alexion, Karyopharm, Seatlle Genetics; Grant/Research Support: Pharmacyclics, Jazz Pharmaceuticals, Astra Zeneca
  • Reinhold Munker:
    Nothing to Disclose

Tags:

hematopoietic cell therapytransplant immunohematology includes serology patient testing component processing recipientpatient hemovigilance - noninfectious adverse events Biotherapies Cellular Therapies and Immunotherapies

All relevant financial relationships have been mitigated. By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.

Credits Available


AM21-37: The Dilemma of Anti - Donor Human Leukocyte Antigen Antibodies and ABO Mismatch in Allogeneic Hematopoietic Cell Transplantation Evaluation